2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-123494
    BRD0418 1565827-99-7
    BRD0418 is a diversity-oriented synthesis (DOS) molecule that regulates the expression of tribbles pseudokinase 1. BRD0418 has the effect of causing hot lipoprotein metabolism from fat production to clearance. BRD0418 can be used in the study of coronary artery disease (CAD) .
    BRD0418
  • HY-124883
    R-(–)-Flecainide 99495-90-6 99.90%
    R-(–)-Flecainide is an orally active antiarrhythmic agent, which inhibits ventricular ectopic activity.
    R-(–)-Flecainide
  • HY-125437
    3-Epidehydrotumulosic acid 167775-54-4 98.14%
    3-Epidehydrotumulosic acid has inhibitory activity against AAPH-induced lysis of red blood cells.
    3-Epidehydrotumulosic acid
  • HY-125772
    Acetyl podocarpic acid anhydride 344327-48-6 ≥99.0%
    Acetyl podocarpic acid anhydride is a potent, semisynthetic liver X receptor(LXR) agonist derived from extracts of the mayapple. Acetyl podocarpic acid anhydride has the potential to be useful for the prevention and research of atherosclerosis, especially in the context of low HDL levels.
    Acetyl podocarpic acid anhydride
  • HY-127026
    Quinaprilat 82768-85-2 98%
    Quinaprilat is an orally active non-mercapto Angiotensin Converting Enzyme (ACE) inhibitor, the active metabolite of Quinapril. Quinaprilat specifically blocks the conversion of angiotensin I to the vasoconstrictor angiotensin II and inhibits the degradation of bradykinin. Quinaprilat acts as anti-hypertensive agent and vasodilator.
    Quinaprilat
  • HY-12765S
    Losartan-d4 (carboxylic acid) 1246820-62-1 98.17%
    Losartan-d4 (carboxylic acid) is the deuterium labeled Losartan (EXP-3174), which is an angiotensin II receptor antagonist.
    Losartan-d4 (carboxylic acid)
  • HY-128696
    Amlodipine aspartic acid impurity 400602-35-9 99.23%
    Amlodipine aspartic acid impurity is the impurity of Amlodipine aspartic acid. Amlodipine aspartic acid is a calcium channel blocker with antihypertensive and antianginal properties.
    Amlodipine aspartic acid impurity
  • HY-129118
    Takeda103A 865609-72-9 ≥98.0%
    Takeda103A is a potent inhibitor of GRK2. G protein-coupled receptors (GPCRs) are central to many physiological processes. Takeda103A has the potential for the research of heart failure.
    Takeda103A
  • HY-129496
    NP-313 5397-78-4 99.58%
    NP-313 is a potent antithrombotic agent that inhibits platelet aggregation and activation. NP-313 has dual inhibition of thromboxane A 2 synthesis and selective inhibition of SOCC-mediated Ca2+ inward flow.
    NP-313
  • HY-130326
    RAPTA-C 372948-28-2 99.30%
    RAPTA-C (Ru(η6-p-cymene)Cl2(pta)) acts as an anti-cancer and anti-angiogenic agent. RAPTA-C exhibits anti-metastatic, anti-angiogenic, and anti-tumoral activities through protein and histone-deoxyribonucleic acid alterations. RAPTA-C exhibits cell growth inhibition by triggering G(2)/M phase arrest in cancer cells. RAPTA-C also enhances the levels of p53 and triggers the mitochondrial Apoptotic pathway, resulting in cytochrome C release and caspase-9 activation. RAPTA-C reduces the growth of tumors with the inhibition of angiogenesis in a ovarian carcinoma model.
    RAPTA-C
  • HY-130345
    PAF (C18) 74389-69-8 99.00%
    C18-PAF, octadecane PAF, is the ligand of platelet-activating factor and PAF G protein-coupled receptor (PAFR). C18-PAF has renovasodilator properties and antihypertensive lipid properties. C18-PAF increases renal blood flow and causes dose-dependent systemic hypotension.
    PAF (C18)
  • HY-131276
    Olmesartan lactone impurity 849206-43-5 99.27%
    Olmesartan lactone impurity is a cyclic ester impurity of Olmesartan. Olmesartan is an angiotensin II receptor (AT1R) antagonist and has the potential for high blood pressure study.
    Olmesartan lactone impurity
  • HY-131722
    EA4 389614-94-2 98.75%
    EA4, a derivative of quinone, is an inhibitor for both rPLA and cPLA. EA4 can inhibit rPLA2 with a Ki value of 130 μM. EA4 can be used for the research of hemostasis, thrombosis, and erythropoiesis.
    EA4
  • HY-135910
    3,4-Dehydro Cilostazol 73963-62-9 98.09%
    3,4-Dehydro Cilostazol (OPC-13015) is an active metabolite of Cilostazol (CLZ; HY-17464). 3,4-Dehydro Cilostazol is used for pharmacokinetic study.
    3,4-Dehydro Cilostazol
  • HY-138647
    TGP-377/421 16752-89-9 99.43%
    TGP-377/421 (Targapre-miR-377/421) is a potent miR-377 and miR-421 inhibitor that binds a functional site in both miRNAs.
    TGP-377/421
  • HY-14187S
    Amiodarone-d10 hydrochloride 1261393-77-4 98.81%
    Amiodarone-d10 (hydrochloride) is the deuterium labeled Amiodarone. Amiodarone hydrochloride is an antiarrhythmic agent for inhibition of ATP-sensitive potassium channel with an IC50 of 19.1 μM.
    Amiodarone-d10 hydrochloride
  • HY-14233S
    Omecamtiv mecarbil-d8 98%
    Omecamtiv mecarbil-d8 is the deuterium labeled Omecamtiv mecarbil. Omecamtiv mecarbil (CK-1827452) is a selective cardiac myosin activator.
    Omecamtiv mecarbil-d8
  • HY-145463
    α-Methylserotonin 304-52-9 98%
    α-Methylserotonin is a potent and selective agonist of 5-HT2 receptor. α-Methylserotonin is an analogue of serotonin formed in vivo from α-methyltryptophan. α-Methylserotonin mediates the lymphatic smooth muscle contraction and prevents the up-regulation of serotonin-receptor-mediated phosphoinositide hydrolysis.
    α-Methylserotonin
  • HY-148037
    Thrombin inhibitor 5 328108-09-4 99.65%
    Thrombin inhibitor 5 (compound 385) is a thrombin inhibitor, with IC50s ranging from 0.1 μM to 1 μM. Thrombin inhibitor 5 can be used for research of venous thromboembolism.
    Thrombin inhibitor 5
  • HY-148136
    sEH inhibitor-7 340221-20-7 99.71%
    sEH inhibitor-7 (compound c-2) is an inhibitor of soluble epoxide hydrolase (sEH) with IC50s of 0.15 μM (mouse sEH) and 6.2 μM (human sEH), respectively. soluble epoxide hydrolase (sEH) plays an important role in the metabolism of endogenous chemical mediators involved in the regulation of blood pressure and inflammation.
    sEH inhibitor-7
Cat. No. Product Name / Synonyms Application Reactivity